WO2011057160A3 - Method to improve the immunogenicity of vaccine antigens by modification of cleavage sites in hiv-1 gp 120 - Google Patents
Method to improve the immunogenicity of vaccine antigens by modification of cleavage sites in hiv-1 gp 120 Download PDFInfo
- Publication number
- WO2011057160A3 WO2011057160A3 PCT/US2010/055747 US2010055747W WO2011057160A3 WO 2011057160 A3 WO2011057160 A3 WO 2011057160A3 US 2010055747 W US2010055747 W US 2010055747W WO 2011057160 A3 WO2011057160 A3 WO 2011057160A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- immunogenicity
- cleavage sites
- hiv
- vaccine antigens
- modification
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Disclosed are novel methods for altering the immunogenicity of vaccine antigens by mutation of cleavage sites recognized by proteases involved in antigen presentation and processing. Also disclosed are therapeutic compositions, vaccines and methods for treating or preventing HIV and other viral diseases.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/079,472 US9782472B2 (en) | 2008-10-04 | 2011-04-04 | Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity |
US15/694,388 US10201603B2 (en) | 2008-10-04 | 2017-09-01 | Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25883309P | 2009-11-06 | 2009-11-06 | |
US61/258,833 | 2009-11-06 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/053637 Continuation-In-Part WO2011050222A2 (en) | 2008-10-04 | 2010-10-22 | Therapeutic compositions that disrupt the hydrogen bonded ring structure in gp41 and methods for treating hiv |
US13/079,472 Continuation-In-Part US9782472B2 (en) | 2008-10-04 | 2011-04-04 | Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2011057160A2 WO2011057160A2 (en) | 2011-05-12 |
WO2011057160A8 WO2011057160A8 (en) | 2011-08-18 |
WO2011057160A3 true WO2011057160A3 (en) | 2011-10-27 |
Family
ID=43970799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/055747 WO2011057160A2 (en) | 2008-10-04 | 2010-11-05 | Method to improve the immunogenicity of vaccine antigens by modification of cleavage sites in hiv-1 gp 120 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2011057160A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015084986A1 (en) * | 2013-12-03 | 2015-06-11 | The Johns Hopkins University | Methods of evaluating immunodominant epitopes |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030091594A1 (en) * | 1999-05-24 | 2003-05-15 | University Of Pennsylvania | CD4-independent HIV envelope proteins as vaccines and therapeutics |
US20040191269A1 (en) * | 2002-12-03 | 2004-09-30 | Shan Lu | Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods |
US20080032921A1 (en) * | 2006-05-18 | 2008-02-07 | Pharmexa Inc. | Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions |
WO2009121914A1 (en) * | 2008-04-02 | 2009-10-08 | Novartis Ag | Substituted piperidines as therapeutic compounds |
-
2010
- 2010-11-05 WO PCT/US2010/055747 patent/WO2011057160A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030091594A1 (en) * | 1999-05-24 | 2003-05-15 | University Of Pennsylvania | CD4-independent HIV envelope proteins as vaccines and therapeutics |
US20040191269A1 (en) * | 2002-12-03 | 2004-09-30 | Shan Lu | Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods |
US20080032921A1 (en) * | 2006-05-18 | 2008-02-07 | Pharmexa Inc. | Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions |
WO2009121914A1 (en) * | 2008-04-02 | 2009-10-08 | Novartis Ag | Substituted piperidines as therapeutic compounds |
Also Published As
Publication number | Publication date |
---|---|
WO2011057160A2 (en) | 2011-05-12 |
WO2011057160A8 (en) | 2011-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007024941A3 (en) | Polyvalent vaccine | |
WO2010019262A3 (en) | Polyvalent vaccine | |
WO2007095318A3 (en) | Influenza antigens, vaccine compositions, and related methods | |
WO2007095320A3 (en) | Hpv antigens, vaccine compositions, and related methods | |
EA201391496A1 (en) | IMMUNOGENIC COMPOSITIONS AND METHODS OF APPLICATION OF SUCH COMPOSITIONS FOR INDUCTION OF HUMORAL AND CELLULAR IMMUNE RESPONSE | |
MX361139B (en) | Influenza virus mutants and uses therefor. | |
EP3266464A3 (en) | Yeast-based therapeutic for chronic hepatitis b infection | |
MX2018010586A (en) | Sting activating nanovaccine for immunotherapy. | |
WO2013006688A3 (en) | N-terminal deleted gp120 immunogens | |
TW200806316A (en) | Yeast-based vaccine for inducing an immune response | |
BR112012033767A2 (en) | process for producing a virus of interest, for removing an adventitious agent, and for removing an adventitious agent, virus, and immunogenic composition or vaccine. | |
TW200722101A (en) | Novel composition | |
WO2008039267A3 (en) | Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions | |
WO2012045001A3 (en) | Influenza virus antibodies and immunogens and uses therefor | |
BR112013011194A2 (en) | rabies virus-like glycoprotein particles (vlps). | |
WO2008134643A3 (en) | Trypanosoma antigens, vaccine compositions, and related methods | |
EA201290956A1 (en) | VACCINE AGAINST HIV | |
IN2012DN03209A (en) | ||
WO2014160747A3 (en) | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection | |
WO2008048344A3 (en) | Bacillus anthracis antigens, vaccine compositions, and related methods | |
WO2014036345A3 (en) | Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins | |
WO2012003234A3 (en) | Env trimer immunogens | |
AU2017261706A1 (en) | Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process | |
IN2014KN02740A (en) | ||
MX2007002659A (en) | Vaccine composition against hepatitis c virus. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10829206 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10829206 Country of ref document: EP Kind code of ref document: A2 |